Merck KGaA

Executive Summary

Merck KGaA is a diversified science and technology leader with three core segments: Healthcare, Life Science, and Electronics. The Healthcare division focuses on innovative prescription medicines and biopharmaceuticals, with a pipeline targeting oncology and neurology. The Life Science segment provides critical tools for research and biomanufacturing, while Electronics supplies advanced materials for semiconductors and displays. This diversification provides revenue stability, though Healthcare pipeline risks remain. Recent regulatory approvals and strong demand in Life Science and Electronics underpin growth. Key upcoming catalysts include pivotal data readouts and label expansions for high-potential drugs, positioning the company for potential value inflection.

Upcoming Catalysts (preview)

• H2 2026Evobrutinib Phase 3 multiple sclerosis data60% success
• 2026Tepotinib label expansion for NSCLC (METex14 skipping)70% success
• H1 2027Bintrafusp alfa Phase 3 combination trial results in biliary tract cancer40% success